

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**開拓藥業有限公司\***  
**KINTOR PHARMACEUTICAL LIMITED**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 9939)**

**(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND**  
**(2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes in the composition of the Board.

(1) Mr. Weipeng Gao (“**Mr. Gao**”) has resigned as a non-executive Director of the Company with effect from 11 December 2025; and

(2) Mr. Yunfei Chen (“**Mr. Chen**”) has been appointed as a non-executive Director of the Company with effect from 11 December 2025.

**RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The Board hereby announces that Mr. Gao has resigned as a non-executive director of the Company with effect from 11 December 2025 due to his other business and personal commitments which require more of his dedication.

Mr. Gao has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude and appreciation to Mr. Gao for his valuable contribution to the Company during his tenure of service.

## APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board further announces that Mr. Chen has been appointed as a non-executive Director of the Company with effect from 11 December 2025.

The biographical details of Mr. Chen are set out as follow:

Mr. Yunfei Chen, aged 41, graduated with a master's degree in microbiology and biochemical pharmacy from Wuhan University in June 2009. He obtained a master of Finance in MBA from Cheung Kong Graduate School of Business (長江商學院) in November 2020. From July 2009 to September 2016, he served as the head of research and development at Shenzhen HEC Industrial Development Co., Ltd. (深圳市東陽光實業發展有限公司). From September 2016 to June 2017, he worked as a project manager at JW Therapeutics (Shanghai) Co., Ltd. (上海藥明巨諾生物科技股份有限公司). Since 1 July 2017, he has held various positions at Suzhou Oriza Holdings Corporation (蘇州元禾控股股份有限公司), including senior investment manager, deputy general manager, and general manager in the healthcare investment department. Since 19 July 2018, he has been a director of the Suzhou GenePharma Co.,Ltd (蘇州吉瑪基因股份有限公司), a company quoted on the National Equities Exchange and Quotations (stock code: 430601). Since 16 December 2020, he has served as a supervisor of Suzhou Kintor Pharmaceutical Inc., a subsidiary of the Company. Since 16 May 2025, he has been a non-independent director of the CareRay Digital Medical Technology Co., Ltd. (江蘇康眾數字醫療科技股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688607).

Mr. Chen has entered into a service contract with the Company for an initial term of three years commencing on 11 December 2025. Such service contract may be terminated by not less than one month's notice in writing served by either party on the other. Mr. Chen is subject to retirement and re-election at the next following annual general meeting of the Company after his appointment and thereafter subject to retirement by rotation and re-election at least once in every three years in accordance with the articles of association of the Company. Mr. Chen will not be entitled to any director's remuneration for his appointment as a non-executive Director.

Save as disclosed above, to the best knowledge and belief of the Board and having made all reasonable enquiries, as at the date of this announcement, Mr. Chen (i) does not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years nor other major appointments and professional qualifications; (ii) does not have any relationship with any Directors, senior management or substantial or controlling Shareholders (each as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")) of the Company; (iii) does not hold any other position with the Company or any of its subsidiaries; and (iv) does not have or is not deemed to have any interests in shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the laws of Hong Kong).

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Chen as a non-executive Director that need to be brought to the attention of the Shareholders or the Stock Exchange, nor is there any other information that should be disclosed by the Company pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to welcome Mr. Chen to the Board.

By order of the Board  
**KINTOR PHARMACEUTICAL LIMITED**  
**Dr. Youzhi Tong**  
*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, 11 December 2025

*As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Yunfei Chen and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.*

*\* For identification purpose only*